Latest News
P95 Partners in South Africa’s Historic Cholera Vaccine Clinical Trial (OcV-S)
P95 is proud to serve as the selected CRO for the cholera vaccine clinical trial of OCV-S, South Africa’s first fully homegrown vaccine
Running Vaccine Trials in Africa: What You Need to Know
Learn about about what it truly takes to run vaccine trials in Africa today in this podcast episode
Expanding with Purpose: P95 Opens New Offices in Ghana and Kenya to Strengthen Vaccine Research Across Africa
In April 2025, P95 proudly opened two new offices on the African continent, in Kenya and Ghana, reinforcing regional impact and collaboration
Pharmacovigilance support in global clinical trials: insights from the CPIVC webinar
P95 shares pharmacovigilance support in global clinical trials through key regulatory insights presented at the CPIVC webinar
The Importance of Medical Writing for Infectious Disease and Vaccine Programs
See how P95 can support with medical writing for vaccine programs or infectious disease research from regulatory documents to protocols
P95 Partners in South Africa’s Historic Cholera Vaccine Clinical Trial (OcV-S)
P95 is proud to serve as the selected CRO for the cholera vaccine clinical trial of OCV-S, South Africa’s first fully homegrown vaccine
P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence
P95 and Julius Clinical merge forming a 500+ person global CRO spanning 25+ countries with operations in North America, Europe, Africa, Latin America, and Asia-Pacific
Latest Press
P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence
P95 and Julius Clinical merge forming a 500+ person global CRO spanning 25+ countries with operations in North America, Europe, Africa, Latin America, and Asia-Pacific
P95 Partners in South Africa’s Historic Cholera Vaccine Clinical Trial (OcV-S)
P95 is proud to serve as the selected CRO for the cholera vaccine clinical trial of OCV-S, South Africa’s first fully homegrown vaccine
P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence
P95 and Julius Clinical merge forming a 500+ person global CRO spanning 25+ countries with operations in North America, Europe, Africa, Latin America, and Asia-Pacific
P95 and LatinaBA enter a strategic partnership to propel vaccine research in Latin America
P95 and LatinaBA are pleased to announce their strategic partnership, aimed at propelling vaccine and infectious disease research in Latin America.
P95 Acquires Assign DMB, Expanding Data Management and Biostatistics Services
P95, a leading global provider of epidemiology and clinical solutions with a specialty focus on vaccines and infectious diseases, is excited to announce the acquisition of Assign DMB.
P95 Company News
View All
Expanding with Purpose: P95 Opens New Offices in Ghana and Kenya to Strengthen Vaccine Research Across Africa
In April 2025, P95 proudly opened two new offices on the African continent, in Kenya and Ghana, reinforcing regional impact and collaboration
P95 Transforming Exercise into Charitable Impact
At P95, we believe in the power of movement – not just as a means to personal health, but as a catalyst for global change. Our Strava group, an initiative that promotes health and fitness within the team, has successfully translated the time logged over the last year into substantial donations for three charities that make a real difference.
Laurence De Moerlooze Joins P95 as Chief Medical Officer
P95 BV, an Ampersand Capital Partners portfolio company, is proud to announce the appointment of Laurence De Moerlooze as Chief Medical Officer (CMO).
Celebrating P95’s Anniversary: From our Humble Beginnings to a Global Full-Service CRO
As we approach our 13th anniversary on June 16, we pause to celebrate important milestones and extend our deepest gratitude to our staff, partners and clients who have been part of our growth journey!
P95’s Journey From Epidemiology Consulting to Comprehensive CRO
In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).
Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.
Events News
View All
How to Design Phase I Vaccine Studies in Europe Webinar
The How to Design Phase I Vaccine Studies in Europe Webinar is a focused session for sponsors and biotech leaders...
Pharmacovigilance support in global clinical trials: insights from the CPIVC webinar
P95 shares pharmacovigilance support in global clinical trials through key regulatory insights presented at the CPIVC webinar
Advancing Vaccine Research at World Vaccine Congress Washington 2025
As World Vaccine Congress Washington 2025 comes to a close, we reflect on an impactful three days of collaboration, innovation and scientific exchange. It was an honour for P95, a leading vaccine research CRO, to take part in one of the most influential global...
P95 At Vaccine World Asia Congress
P95 successfully exhibited at the Vaccine World Asia Congress 2024, held on 6-7 November in Bangkok, Thailand. The Congress provided a valuable platform for sharing our capabilities and exploring potential collaborators for vaccine development in Asia and globally....
P95 At World Vaccine Congress Europe 2024
This October, the P95 team attended and exhibited at Europe's largest vaccine event, the World Vaccine Congress Europe 2024 held in Barcelona! As a global leading CRO specializing in vaccines and infectious diseases, P95 had a prime location with one of the most...
P95 is a full-service Contract Research Organization (CRO) specializing in clinical trials, epidemiology, and real-world evidence, for vaccines and infectious diseases.